Scholarlink

Background <p>Acute congestive heart failure (AHF) is a leading cause of hospital admission, with decongestion serving as the cornerstone of its treatment. In the absence of congestion-specific quantitative measures, however, undertreatment often occurs and it is associated with an increased risk of readmission. Lung ultrasonography (LUS) has high accuracy for detecting extravascular lung water. Its use for guiding decongestion in ambulatory patients has shown a reduction in hospital admission and urgent outpatient visits, whereas data are lacking for AHF inpatients. Our aim is to investigate the effect of a LUS-guided decongestive therapy on early clinical outcomes, as compared to physical examination, in hospitalised AHF adults.</p> Methods <p>The ICARUS project is a multicentric, multi-blinded, randomised, controlled superiority study, aiming to recruit 222 adult, hospitalised AHF patients with raised values of natriuretic peptide. Participants will be randomised to a decongestive strategy guided by either daily LUS findings (8-point protocol) or daily physical examination. The randomisation will be stratified by study centre and inclusion delay (i.e. within 24&#xa0;h or more). The primary outcome is the number of days spent alive and out of hospital in a 40-day timeframe from study inclusion (DAOH-40). Secondary outcomes include successful decongestion, length of hospital stay (index hospitalisation), early readmission and mortality, dyspnoea and quality of life (EQ-5D-5L).</p> Discussion <p>Incomplete decongestion at discharge is frequent in patients hospitalised for AHF and it is strongly associated with rehospitalisation and mortality. There is a need to clarify the role of LUS as a guide for decongestive therapies. The ICARUS project will provide strong evidence on the usefulness of LUS as a guide for decongestive therapy in hospitalised AHF patients.</p> Trial registration <p>The present protocol is registered in ClinicalTrials.gov (NCT 06465498, registered 20 June 2024, <a href="https://clinicaltrials.gov/study/NCT06465498">https://clinicaltrials.gov/study/NCT06465498</a>) and in the Swiss human research platform HumRes of the Federal Office of Public Health (CCER 2024-00268).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The ICARUS project: study protocol for a randomised controlled trial Investigating aCute heArt failuRe decongestion guided by lung UltraSonography

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月22日

查看全文
  • Antonio Leidi,
  • Tamara Mann,
  • Pauline Gosselin,
  • Michele Bedulli,
  • Fernando Esposito,
  • Claudio Schneider,
  • Thibault Parent,
  • Christophe Combescure,
  • Thibaut Desmettre,
  • Jean-Luc Reny,
  • Jérôme Stirnemann,
  • Olivier Grosgurin,
  • Laetitia Abdou-Garonne,
  • Gwaenaelle Aellen,
  • Gauthier Andreoli,
  • Carole Elodie Aubert,
  • Luca Bettini,
  • Stijn Bex,
  • Romain Bonnet,
  • Tara Bopp,
  • Emanuele Bovio,
  • Giovanni Bruno,
  • Simone Canonica,
  • Sebastien Carballo,
  • Alberto Cerutti,
  • Christophe Marti,
  • Matteo Coen,
  • Luisa Costantini,
  • Jonathan Dash,
  • Elisa Ferrazzini,
  • Sandrine Foucras,
  • Manuel Gloor,
  • Gael Grandmaison,
  • Nadia Grassi,
  • Damien Guijarro,
  • Jacques Serratrice,
  • André Juillerat,
  • Elia Lo Priore,
  • Karine Lopez-Bouhara,
  • Joël Luder,
  • Marco Mancinetti,
  • Sophie Mantelli,
  • Gabriel Marketa,
  • Andreas Marti,
  • Caterina Eva Marx,
  • Simona Maurer,
  • Philippe Meyer,
  • Lara Morosoli,
  • Giorgio Moschovitis,
  • Elisa Mugetti,
  • Franziska Peier,
  • Caroline Pernoud,
  • Nina Pianezzi-Chappex,
  • Vincent Piller,
  • Oana Potinc,
  • Damiana Pulver,
  • Serban-George Puricel,
  • Martine Rime,
  • Caroline Rimensberger,
  • Mathilde Rochat,
  • Maxime Schmutz,
  • Guillaume Soret,
  • Nora Sutter,
  • Maria Trachsel,
  • Guido Trinci,
  • Salome Tschan,
  • Valerian Valiton,
  • Annina Von Allmen

摘要

Background

Acute congestive heart failure (AHF) is a leading cause of hospital admission, with decongestion serving as the cornerstone of its treatment. In the absence of congestion-specific quantitative measures, however, undertreatment often occurs and it is associated with an increased risk of readmission. Lung ultrasonography (LUS) has high accuracy for detecting extravascular lung water. Its use for guiding decongestion in ambulatory patients has shown a reduction in hospital admission and urgent outpatient visits, whereas data are lacking for AHF inpatients. Our aim is to investigate the effect of a LUS-guided decongestive therapy on early clinical outcomes, as compared to physical examination, in hospitalised AHF adults.

Methods

The ICARUS project is a multicentric, multi-blinded, randomised, controlled superiority study, aiming to recruit 222 adult, hospitalised AHF patients with raised values of natriuretic peptide. Participants will be randomised to a decongestive strategy guided by either daily LUS findings (8-point protocol) or daily physical examination. The randomisation will be stratified by study centre and inclusion delay (i.e. within 24 h or more). The primary outcome is the number of days spent alive and out of hospital in a 40-day timeframe from study inclusion (DAOH-40). Secondary outcomes include successful decongestion, length of hospital stay (index hospitalisation), early readmission and mortality, dyspnoea and quality of life (EQ-5D-5L).

Discussion

Incomplete decongestion at discharge is frequent in patients hospitalised for AHF and it is strongly associated with rehospitalisation and mortality. There is a need to clarify the role of LUS as a guide for decongestive therapies. The ICARUS project will provide strong evidence on the usefulness of LUS as a guide for decongestive therapy in hospitalised AHF patients.

Trial registration

The present protocol is registered in ClinicalTrials.gov (NCT 06465498, registered 20 June 2024, https://clinicaltrials.gov/study/NCT06465498) and in the Swiss human research platform HumRes of the Federal Office of Public Health (CCER 2024-00268).